Brenipatide + Placebo + Buprenorphine
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Opioid Use Disorder
Conditions
Opioid Use Disorder
Trial Timeline
Feb 13, 2026 → Feb 1, 2028
NCT ID
NCT07420283About Brenipatide + Placebo + Buprenorphine
Brenipatide + Placebo + Buprenorphine is a phase 2 stage product being developed by Eli Lilly for Opioid Use Disorder. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07420283. Target conditions include Opioid Use Disorder.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07420283 | Phase 2 | Recruiting |
Competing Products
20 competing products in Opioid Use Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SUBLOCADE | Indivior PLC | Phase 3 | 72 |
| SUBLOCADE | Indivior PLC | Phase 3 | 72 |
| ASP8082 + morphine + Placebo | Astellas Pharma | Phase 1 | 33 |
| ASP8062 + Placebo ASP8062 + buprenorphine/naloxone | Astellas Pharma | Phase 1 | 33 |
| ASP8062 + Placebo ASP8062 + buprenorphine/naloxone | Astellas Pharma | Phase 2 | 52 |
| Naldemedine + Placebo | Shionogi | Phase 3 | 77 |
| Naldemedine + Placebo | Shionogi | Approved | 85 |
| Naldemedine | Shionogi | Phase 1/2 | 41 |
| Naldemedine + Placebo | Shionogi | Phase 3 | 77 |
| Placebo + Naldemedine | Shionogi | Phase 2 | 52 |
| Naldemedine + Placebo | Shionogi | Phase 3 | 77 |
| Naldemedine + Placebo | Shionogi | Phase 2 | 52 |
| Naloxegol | Kyowa Kirin | Pre-clinical | 23 |
| naloxegol + non-PAMORA laxative | Kyowa Kirin | Pre-clinical | 23 |
| Naloxegol | Kyowa Kirin | Pre-clinical | 23 |
| Naloxegol | Kyowa Kirin | Pre-clinical | 23 |
| NKTR-118 + NKTR-118 + Placebo | AstraZeneca | Phase 3 | 77 |
| Naloxegol + Naloxegol | AstraZeneca | Phase 1 | 33 |
| NKTR-118 + Usual care | AstraZeneca | Phase 3 | 77 |
| Polyethylene Glycol 3350 + Movantik | AstraZeneca | Approved | 85 |